The Use of Hallucinogens in the Treatment of Addiction
Addiction Research & Theory 1996 DOI: 10.3109/16066359609010756 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Placebo-controlled Double-blind Peer reviewed |
|---|---|
| Topics | Addiction |
| Keywords | Hallucinogen |
| Citations | 63 |
| Key findings | Anti-craving properties may be present across the entire family of hallucinogens, potentially tied to their agonism and antagonism at specific serotonin receptor sites. |
Abstract
AbstractResearch into treating drug dependence with hallucinogens, although promising, ended with questions still unanswered because of varying, in some cases skeptical, methodology and insufficient adherence to a double-blind, placebo-controlled design. Interest is again emerging, especially with the recent patenting in the United States of ibogaine for its apparent anti-craving properties. A review of the literature shows that these properties may be present across the entire family of hallucinogens. Potential efficacy may be tied to their agonism and antagonism at specific serotonin receptor sites. After the administration of a hallucinogen, there is a positive "afterglow" lasting weeks to months which might be extended through repeated dosing. Ibogaine and LSD both have lengthy periods of action, making their application unwieldy. However, tryptamines, such as N,N-Dimethyltryptamine (DMT), are so short-acting that they could easily be administered in an office setting. With numerous hallucinogens yet to be tested, a hallucinogen might well be discovered with superior anti-craving properties and non-deleterious side-effect profile.Key Words: LSDIbogaineN.N-Dimethyltryptamine (DMT)Therapeutic UseDrug DependenceSerotonin
Comparable studies
Other narrative reviews on addiction, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| Mindfulness meditation–based pain relief: a mechanistic account | 2016 | Review | |
| Psychedelics as anti-inflammatory agents Animal models and cellular studies | 2018 | Review | |
| A narrative review of yoga and mindfulness as complementary therapies for addiction. | 2013 | Review | |
| The neuropsychopharmacology of cannabis: A review of human imaging studies | 2018 | Review |
Citations in the library
Cited by 50
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
- Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness Journal of Psychopharmacology September 28, 2011
- Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics May 1, 2019
and 45 more in the library
Cites 40
- Dose-Response Study of N,N-Dimethyltryptamine in Humans Archives of General Psychiatry February 1, 1994
- ADVERSE REACTIONS TO PSYCHEDELIC DRUGS. A REVIEW OF THE LITERATURE The Journal of Nervous and Mental Disease October 1, 1984
- Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience July 1, 1993
- The Experimental Use of Psychedelic (LSD) Psychotherapy JAMA June 15, 1970
- LSD-Assisted Psychotherapy in Patients with Terminal Cancer International Pharmacopsychiatry 1973
and 35 more in the library